This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie policy for more information on the cookies we use and how to delete or block them.
Atmo Biosciences, a digital health company that is developing the world’s first ingestible gas-sensing capsule for monitoring gut health, has closed an oversubscribed A$9.6m capital raise.
Planet Innovation is redefining what it means to be a strategic investor by providing investee companies with not just funding, but access to its people, facilities and networks.
Lumos Diagnostics, a PI investee company, has been admitted to the Australian Securities Exchange (ASX) with trading commencing on July 5 after raising $63 million AUD in an Initial Public Offering (IPO).
Atmo Biosciences is ramping up manufacture of its third generation gas-sensing capsule at Planet Innovation’s recently opened new medtech manufacturing facility.
PI’s business model has been proven a success with another of its investee companies – Visus Therapeutics™ – raising $US36 ($A47) million in Series A financing.
Visus Therapeutics, a company backed by Planet Innovation, has started a clinical development program for a novel eye drop designed to restore the loss of near vision associated with aging.
Atmo Biosciences has been awarded a $620,000 Australian Government grant through the BioMedTech Horizons (BMTH) program.
Atmo Biosciences, a digital health business that provides objective real-time insights into gut health and microbiome function, has raised a further A$2.5 million in an oversubscribed funding round, supplementing an initial seed raise in March 2019.
A roundup of the latest news and opinions from PI.
Seed Health, a US-based microbial sciences company, and Atmo Biosciences, a Planet Innovation early stage venture, have announced a partnership to use Atmo’s ingestible gas-sensing capsule to study the impact of probiotics on the gut microbiome.
November 18-24 is World Antibiotic Awareness Week, so it’s a good time to draw attention to the global health challenge of antibiotic resistance, which Planet Innovation is combating through its business Lumos Diagnostics.
Atmo Biosciences, a Planet Innovation early stage venture, has signed a licensing deal with RMIT University to secure the exclusive worldwide rights to a ground-breaking ingestible gas-sensing capsule.
Lumos Diagnostics is expanding its global footprint after agreeing an ongoing manufacturing deal for a customized lateral flow reader with a California-based life sciences company.
Planet Innovation has launched Vitalic Medical, a digital health venture addressing two major problems for general wards in hospitals around the world: undetected patient deterioration and in-hospital patient falls.
Lumos Diagnostics develops custom products for its partners using a unique combination of integrated assay and engineering capability paired with its proven reader optical technologies.
Zen Ecosystems has received a major grant by the Australian Renewable Energy Agency (ARENA) to help secure Australia’s energy supplies during times of peak demand.
Planet Innovation’s PoC (Point-of-Care) diagnostic platform, Nplex, will benefit from further investment to develop a cloud-connected medical counter-measures device, for the rapid detection of infectious diseases.
Zen Thermostat, a PI venture, has been selected by Telstra to be sold as part of its soon to be released Smart Home Platform.
Zen is a smart thermostat launched by Planet Innovation with a successful crowd funding campaign.
Diagnostics
Life Sciences
Medical Devices
Internet of Things